Company profile
AXON Neuroscience
Independent clinical stage biotech company.
- Industry
- Biotechnology Research
- Employees
- 32
- Headquarters
- Bratislava
- Founded
- 1999
- Office locations
- 1
AXON Neuroscience company summary
AXON Neuroscience is a company in the Biotechnology Research industry, headquartered in Bratislava, founded in 1999. On LinkedIn the company has around 32 employees. Its listed specialties include Disease modifying pharmaceuticals and diagnostic methods for Alzheimer’s disease.
What technology does AXON Neuroscience use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About AXON Neuroscience
Axon Neuroscience is a clinical-stage biotechnology leader pioneering tau-targeted therapies to prevent and treat Alzheimer’s disease and related neurodegenerative disorders. Founded in 1999 by Prof. Michal Novak, who discovered the tau protein as a key cause of Alzheimer’s disease, Axon has built the world’s largest dedicated tau research team with over 20 senior in-house scientists advancing cutting-edge programs from discovery to clinical development. Axon’s lead candidate, AADvac1, is the most clinically advanced active vaccine targeting pathological tau. In the successful Phase II ADAMANT study, AADvac1 showed excellent safety and immunogenicity, with over 80% of patients developing strong anti-tau antibodies. Axon demonstrated consistent biomarker efficacy across NfL, GFAP, and MRI volumetry, alongside a trending clinical benefit — validating its disease-modifying potential. Building on this foundation, Axon is advancing AADvac1 into two major international platform trials starting in 2026: The Alzheimer’s Tau Platform (ATP) enrolling 375 patients with early Alzheimer’s, evaluating AADvac1 alone and in combination with anti-amyloid antibodies. The Progressive Supranuclear Palsy (PSP) Phase II Platform Trial, enrolling 220 patients, expanding AADvac1’s potential across tauopathies beyond Alzheimer’s. Axon’s diversified pipeline also includes a humanized anti-tau monoclonal antibody (AADvac2), and small-molecule programs targeting tau aggregation and propagation. With over two decades of pioneering science and consistent clinical validation, Axon Neuroscience is transforming the future of brain health with the promise of first-in-class, disease-modifying therapies for millions suffering worldwide.
Specialties
Where is AXON Neuroscience located?
AXON Neuroscience lists 1 location.
Compare companies similar to AXON Neuroscience
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
AXON Neuroscience axon-neuroscience.eu | Biotechnology Research | 32 | 1999 | Bratislava |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about AXON Neuroscience
What does AXON Neuroscience do?
Axon Neuroscience is a clinical-stage biotechnology leader pioneering tau-targeted therapies to prevent and treat Alzheimer’s disease and related neurodegenerative disorders. Founded in 1999 by Prof. Michal Novak, who discovered the tau protein as a key cause of Alzheimer’s disease, Axon has built the world’s largest dedicated tau research team with over 20 senior in-house scientists advancing cutting-edge programs from discovery to clinical development. Axon’s lead candidate, AADvac1, is the most clinically advanced active vaccine targeting pathological tau. In the successful Phase II ADAMANT study, AADvac1 showed excellent safety and immunogenicity, with over 80% of patients developing strong anti-tau antibodies. Axon demonstrated consistent biomarker efficacy across NfL, GFAP, and MRI volumetry, alongside a trending clinical benefit — validating its disease-modifying potential. Building on this foundation, Axon is advancing AADvac1 into two major international platform trials starting in 2026: The Alzheimer’s Tau Platform (ATP) enrolling 375 patients with early Alzheimer’s, evaluating AADvac1 alone and in combination with anti-amyloid antibodies. The Progressive Supranuclear Palsy (PSP) Phase II Platform Trial, enrolling 220 patients, expanding AADvac1’s potential across tauopathies beyond Alzheimer’s. Axon’s diversified pipeline also includes a humanized anti-tau monoclonal antibody (AADvac2), and small-molecule programs targeting tau aggregation and propagation. With over two decades of pioneering science and consistent clinical validation, Axon Neuroscience is transforming the future of brain health with the promise of first-in-class, disease-modifying therapies for millions suffering worldwide.
How many employees does AXON Neuroscience have?
AXON Neuroscience has around 32 employees on LinkedIn.
Where is AXON Neuroscience headquartered?
AXON Neuroscience is headquartered in Bratislava.
When was AXON Neuroscience founded?
AXON Neuroscience was founded in 1999.
Build a lead list from companies like AXON Neuroscience
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.